Remove 2026 Remove Chemotherapy Remove Communication
article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Sign up for our daily news round-up!

FDA